DrugPatentWatch Database Preview
IDHIFA Drug Profile
Which patents cover Idhifa, and when can generic versions of Idhifa launch?
Idhifa is a drug marketed by Celgene Corp and is included in one NDA. There are five patents protecting this drug.
This drug has seventy-five patent family members in thirty-four countries.
The generic ingredient in IDHIFA is enasidenib mesylate. One supplier is listed for this compound. Additional details are available on the enasidenib mesylate profile page.
Summary for IDHIFA
| International Patents: | 75 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 42 |
| Clinical Trials: | 5 |
| Patent Applications: | 26 |
| Drug Prices: | Drug price information for IDHIFA |
| DailyMed Link: | IDHIFA at DailyMed |
Generic Entry Opportunity Date for IDHIFA
Generic Entry Date for IDHIFA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for IDHIFA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| AbbVie | Phase 1/Phase 2 |
| Celgene | Phase 1/Phase 2 |
| University Health Network, Toronto | Phase 1/Phase 2 |
Pharmacology for IDHIFA
| Drug Class | Isocitrate Dehydrogenase 2 Inhibitor |
| Mechanism of Action | Isocitrate Dehydrogenase 2 Inhibitors |
Synonyms for IDHIFA
| 1446502-11-9 |
| 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol |
| 2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol |
| 2-Methyl-1-[(4-[6-(Trifluoromethyl)pyridin-2-Yl]-6-{[2-(Trifluoromethyl)pyridin-4-Yl]amino}-1,3,5-Triazin-2-Yl)amino]propan-2-Ol |
| 2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol |
| 2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)- |
| 3T1SS4E7AG |
| 69Q |
| AG 221 |
| AG-221 |
| AG-221 (Enasidenib) |
| AG-221; Enasidenib |
| AG-221(Enasidenib) |
| AG221 |
| AKOS026750439 |
| BCP16041 |
| CC 90007 |
| CC-90007 |
| CC-90007 Free Base |
| CC90007 |
| CHEMBL3989908 |
| CS-5017 |
| D10901 |
| DB13874 |
| Enasidenib |
| Enasidenib (USAN/INN) |
| Enasidenib [INN] |
| Enasidenib [USAN:INN] |
| Enasidenib mesylate |
| EX-A654 |
| FT-0700204 |
| GTPL8960 |
| HY-18690 |
| J-690181 |
| KB-3356927 |
| KS-000006AW |
| NCGC00479249-03 |
| NCGC00479249-05 |
| s8205 |
| SB19193 |
| SCHEMBL15102202 |
| UNII-3T1SS4E7AG |
| ZINC222731806 |
US Patents and Regulatory Information for IDHIFA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-001 | Aug 1, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-001 | Aug 1, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-001 | Aug 1, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for IDHIFA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | I666208 | Start Trial |
| Peru | 20982014 | Start Trial |
| South Korea | 20160037195 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
